Healthcare provider profile · identity verified

Sneha Patel, MD

Internal Medicine · FREMONT, CA · NPI 1255416939

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	169	35
Furosemide	Furosemide	134	23
Donepezil Hcl	Donepezil Hcl	109	29
Gabapentin	Gabapentin	99	14
Trazodone Hcl	Trazodone Hcl	94	31
Humulin R	Insulin Regular, Human	91	14
Metoprolol Tartrate	Metoprolol Tartrate	81	14
Amlodipine Besylate	Amlodipine Besylate	76	19
Pantoprazole Sodium	Pantoprazole Sodium	76	14
Pradaxa	Dabigatran Etexilate Mesylate	76	12
Mirtazapine	Mirtazapine	74	12
Warfarin Sodium	Warfarin Sodium	60	suppressed
Potassium Chloride	Potassium Chloride	57	suppressed
Metformin Hcl	Metformin Hcl	54	12
Chlorhexidine Gluconate	Chlorhexidine Gluconate	47	20
Memantine Hcl	Memantine Hcl	45	16
Latanoprost	Latanoprost	43	suppressed
Prednisone	Prednisone	43	suppressed
Lisinopril	Lisinopril	40	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	38	11
Lovastatin	Lovastatin	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Famotidine	Famotidine	32	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	suppressed
Sertraline Hcl	Sertraline Hcl	31	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	30	suppressed
Omeprazole	Omeprazole	30	suppressed
Cefadroxil	Cefadroxil	29	19
Humulin N	Insulin Nph Human Isophane	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	27	suppressed
Levetiracetam	Levetiracetam	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	25	suppressed
Jardiance	Empagliflozin	24	suppressed
Sildenafil Citrate	Sildenafil Citrate	24	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	23	suppressed
Terazosin Hcl	Terazosin Hcl	23	suppressed
Myrbetriq	Mirabegron	22	suppressed
Atenolol	Atenolol	20	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Nystop	Nystatin	20	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	19	suppressed
Losartan Potassium	Losartan Potassium	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	13
Allopurinol	Allopurinol	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Trospium Chloride	Trospium Chloride	15	suppressed
Albuterol Sulfate	Albuterol Sulfate	14	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	14	suppressed
Hydroxyurea	Hydroxyurea	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Timolol Maleate	Timolol Maleate	14	suppressed
Budesonide	Budesonide	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Theophylline Er	Theophylline Anhydrous	13	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Eliquis	Apixaban	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Baclofen	Baclofen	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Glipizide	Glipizide	11	suppressed
Methimazole	Methimazole	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error